

ESMO VIRTUAL PLENARY

PROSPECTIVE DOUBLE-BLIND, RANDOMIZED PHASE III ENGOT-EN5/GOG-3055/SIENDO STUDY OF ORAL SELINEXOR/PLACEBO AS MAINTENANCE THERAPY AFTER FIRST-LINE CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER

Ignace Vergote,¹ Alejandro Pérez Fidalgo,² Erika Hamilton,³ Giorgio Valabrega,⁴ Toon Van Gorp,¹
Jalid Sehoul,⁵ David Cibula,⁶ Tally Levy,⁷ Stephen Welch,⁸ Debra Richardson,⁹ Eva Maria Guerra
Alfa,¹⁰ Giovanni Scambia,¹¹ Stéphanie Henry,¹² Pauline Wimberger,¹³ David Miller,¹⁴ Jerónimo
Martínez,¹⁵ Bradley Monk,¹⁶ Sharon Shacham,¹⁷ Mansoor Raza Mirza,^{17,18} Vicky Makker¹⁹

¹Catholic University Leuven, Cancer Institute at University Hospitals, Belgium, European Union, ²Hospital Clínico Universitario de Valencia, Spain,
³Sarah Cannon Research Institute USA, ⁴University of Torino, Candiolo Cancer Institute, FPO-IRCCS, Italy, ⁵European Competence Center for
Ovarian Cancer, Charité Comprehensive Cancer Center, Charité-Berlin University of Medicine, Germany, ⁶Charles University and General
Faculty Hospital Prague, Czech Republic, ⁷Wolfson Medical Center, Holon, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Israel,
⁸London Health Sciences Centre, UK ⁹University of Oklahoma Medical Center, USA, ¹⁰Hospital Universitario Ramón y Cajal, Spain, ¹¹Fondazione
Policlinico Universitario A. Gemelli IRCCS, Italy, ¹²Centre de Maternité Sainte Elisabeth, Namur, Belgium, ¹³Technische Universität Dresden,
University Hospital Carl Gustav Carus, Germany, ¹⁴University of Texas Southwestern Medical Center; Harold C. Simmons Comprehensive Cancer
Center, USA, ¹⁵Hospital Universitario Virgen de la Arrixaca, Spain, ¹⁶Biltmore Cancer Center, USA, ¹⁷Karyopharm Therapeutics, USA,
¹⁸Rigshospitalet, Copenhagen University Hospital, Denmark, ¹⁹Memorial Sloan Kettering Cancer Center, USA




DECLARATION OF INTERESTS

Ignace Vergote:

- Consulting for: Agenus, Aksebio, AstraZeneca, Bristol Myers Squibb (2021), Deciphera Pharmaceuticals, Eisai, Elevar Therapeutics, F. Hoffmann-La Roche Ltd, Genmab, GSK, Immunogen Inc., Jazzpharma, Karyopharm, Mersana, MSD, Novocure, Novartis, Oncoinvent AS, Seagen, Sotio a.s., Verastem Oncology, Zentalis
- Contracted Research (via KULeuven): Oncoinvent AS (2019-2020)
- Grant/Corporate Sponsored Research: Amgen, F. Hoffmann-La Roche
- Accommodations, travel expenses: Amgen, MSD, Tesaro, AstraZeneca, Karyopharm, F. Hoffmann-La Roche

SELINEXOR: XPO1 INHIBITION



Exportin 1 (XPO1) is the major nuclear export protein for:¹

- Tumor suppressor proteins (TSPs, e.g., p53, IκB, PTEN, and FOXO1)

Inhibition of XPO1 results in:¹

- The increase in nuclear levels and activation of TSPs
- Reduction of oncoprotein levels

Selinexor is an oral selective XPO1 inhibitor


Preclinical data for selinexor:²

- Reactivates multiple TSPs, including p53 wild type, by preventing nuclear export

¹Fung HY, Chook YM. Semin Cancer Biol. 2014;27:52–61.

²Tai YT, Landesman Y, Acharya C, et al. Leukemia. 2014;28(1):155–165.

SELINEXOR ACTIVITY IN GYNECOLOGICAL MALIGNANCIES



Maximal percent change in tumor size from screening for 19 patients with endometrial cancer. *Indicates platinum-refractory²


- Selinexor, alone or in combination with platinum, reduced tumor growth in platinum-resistant PDX mice as well as ovarian-cancer patients.^{1,2}
- **SIGN phase 2 study²**, selinexor monotherapy in gynecological malignancies (**endometrial** cancer, n=23)
 - **DCR (SD ≥ 12 weeks or a PR)=35%**
(median duration 6.3 months) with 2 (9%) PR
 - OS = 7.0 months
 - PFS = 2.8 months
 - No new safety signals

¹Chen Y, et al. Clin Cancer Res. 2017

²Vergote IB, et al. Gynecol Oncol. 2020

ENGOT-EN5/GOG-3055/SIENDO TRIAL DESIGN

Stage IV or first relapse of endometrial cancer
endometrioid, serous, undifferentiated, or carcinosarcoma
(NCT03555422)




**140 PFS events needed to provide 80% power to detect a hazard ratio of 0.6 (median PFS 4.5 months for placebo and 7.5 months for selinexor) with a one-sided alpha of 0.025 and 2:1 randomization ratio favoring selinexor.

BMI, body mass index; DCR, disease control rate; DSS, disease-specific survival; QW, once weekly; CR, complete response; OS, overall survival; PFS, progression-free survival; PFS2, progression-free survival on subsequent therapy; PR, partial response; PROs, patient-reported outcomes; R, randomized; TFST, time to first subsequent therapy; TSST, time to second subsequent treatment

ENGOT-EN5/GOG-3055/SIENDO

DISPOSITION



PATIENT CHARACTERISTICS


| CHARACTERISTIC | Selinexor N = 174 | Placebo N = 89 |
|--|----------------------|-------------------|
| Age, years median (range), n (%) | 65.5 (40-81) | 64.0 (33-81) |
| <70 years, n (%) | 116 (66.7) | 61 (68.5) |
| ≥70 years, n (%) | 58 (33.3) | 28 (31.5) |
| ECOG performance status, n (%) | | |
| 0 | 99 (56.9) | 54 (60.7) |
| 1 | 71 (40.8) | 35 (39.3) |
| 2 | 1 (0.6) | 0 |
| Histology, n (%) | | |
| Endometrioid | 96 (55.2) | 48 (53.9) |
| Serous | 49 (28.2) | 28 (31.5) |
| Undifferentiated | 4 (2.3) | 1 (1.1) |
| Carcinosarcoma | 10 (5.7) | 6 (6.7) |
| Endometrial Adenocarcinoma* | 15 (8.6) | 6 (6.7) |
| Number of Prior Antineoplastic Regimens, n (%) | | |
| 1 | 172 (98.9) | 85 (95.5) |
| 2/3 | 2 (1.1) | 3 (3.4)/1 (1.1) |
| Disease at Time of Taxane-Platinum Combination Therapy -eCRF, n (%) | | |
| Primary Stage IV Disease | 78 (44.8) | 43 (48.3) |
| Recurrent Disease | 96 (55.2) | 46 (51.7) |
| Disease Status After the Most Recent Chemotherapy -eCRF, n (%) | | |
| CR | 70 (40.2) | 40 (44.9) |
| PR | 104 (59.8) | 49 (55.1) |

*Not otherwise specified CR, complete response; ECOG, Eastern Cooperative Oncology Group; eCRF, electronic case report form; PR, partial response

ENGOT-EN5/GOG-3055/SIENDO

PRIMARY ENDPOINT: PFS IN ITT POPULATION

(BASED ON AUDITED STRATIFICATION FACTORS)*



Median PFS (Investigator assessed)

Selinexor (n=174): 5.7 mo (95% CI 3.81-9.20)

Placebo (n=89): 3.8 mo (95% CI 3.68-7.39)

HR* = 0.705 (95% CI 0.499-0.996)

One-sided P value = 0.024

* In 7 patients (2.7% of 263), the stratification factor of CR/PR was incorrect and was corrected by the Investigators prior to database lock and unblinding.

The statistical analysis was validated by the independent ENGOT statistician and approved by the IDMC.

HR for ITT without correction of the stratification factors was 0.76 (95% CI: 0.543, 1.076).

ESMO VIRTUAL PLenary


Ignace Vergote, MD, PhD

Content of this presentation is copyright and responsibility of the author.
Permission is required for re-use.


SUBGROUP PFS: BY HISTOLOGICAL SUBTYPE

(BASED ON AUDITED STRATIFICATION FACTORS)

Endometrioid Carcinoma




Serous Carcinoma



ENGOT-EN5/GOG-3055/SIENDO

SUBGROUP PFS: PATIENTS WITH WILD TYPE P53 EC

(BASED ON AUDITED STRATIFICATION FACTORS)



Median PFS

Selinexor (n=67): 13.7 mo (95% CI 9.20-NR)

Placebo (n=36): 3.7 mo (95% CI 1.87-12.88)

HR = 0.375 (95% CI 0.210-0.670)

One-sided P value = 0.0003

ESMO VIRTUAL PLenary

Ignace Vergote, MD, PhD


Content of this presentation is copyright and responsibility of the author.
Permission is required for re-use.

SUBGROUP PATIENT CHARACTERISTICS: P53 WILD TYPE

| CHARACTERISTIC | Selinexor N = 67 | Placebo N = 36 |
|--|---------------------|-------------------|
| Age, years median (range), n (%) | 64.0 (40-81) | 61.0 (33-74) |
| <70 years, n (%) | 46 (68.7) | 29 (80.6) |
| ≥70 years, n (%) | 21 (31.3) | 7 (19.4) |
| ECOG performance status, n (%) | | |
| 0 | 36 (53.7) | 23 (63.9) |
| 1 | 30 (44.8) | 13 (36.1) |
| 2 | 1 (1.5) | 0 |
| Histology, n (%) | | |
| Endometrioid | 55 (82.1) | 28 (77.8) |
| Serous | 3 (4.5) | 4 (11.1) |
| Undifferentiated | 0 | 1 (2.8) |
| Carcinosarcoma | 1 (1.5) | 0 |
| Endometrial Adenocarcinoma* | 8 (11.9) | 3 (8.3) |
| Number of Prior Antineoplastic Regimens, n (%) | | |
| 1 | 67 (100.0) | 35 (97.2) |
| 2 | 0 | 1 (2.8) |
| Disease at Time of Taxane-Platinum Combination Therapy -eCRF, n (%) | | |
| Primary Stage IV Disease | 25 (37.3) | 18 (50.0) |
| Recurrent Disease | 42 (62.7) | 18 (50.0) |
| Disease Status After the Most Recent Chemotherapy -eCRF, n (%) | | |
| CR | 29 (43.3) | 16 (44.4) |
| PR | 38 (56.7) | 20 (55.6) |

*Not otherwise specified CR, complete response; ECOG, Eastern Cooperative Oncology Group; eCRF, electronic case report form; PR, partial response

SAFETY: TREATMENT-EMERGENT ADVERSE EVENTS



*Four patients did not receive treatment (n=3 selinexor; n=1 placebo)

**n=1 Grade 4 thrombocytopenia; No cases of severe bleeding in patients with thrombocytopenia; No cases of febrile neutropenia

ENGOT-EN5/GOG-3055/SIENDO





SAFETY

| Event | Selinexor n=171* n (%) (per patient) | Placebo n=88* n (%) (per patient) |
|-------------------|---|--|
| TEAE leading to: | | |
| Dose reduction | 85 (49.7) | 3 (3.4) |
| Dose interruption | 88 (51.5) | 16 (18.2) |
| Discontinuation | 18 (10.5) | 1 (1.1) |
| Death | 0 | 0 |

*Four patients did not receive treatment (n=3 selinexor; n=1 placebo)

QOL -PATIENT-REPORTED OUTCOMES (EORTC QLQ-C30)

No significant differences in global health, physical functioning or symptoms



EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Module

SUMMARY AND CONCLUSIONS

- Selinexor demonstrated in the audited ITT population, a **30% decrease of risk for progression and/or death compared to placebo** (HR: 0.705; CI: 0.499-0.996; median PFS 5.7 vs 3.8 months, respectively) which was statistically significant (one-sided $p=0.024$); In the non-audited ITT population (HR 0.76 (95% CI: 0.543, 1.076; one-sided $p=0.063$)
- Patients with **endometrioid** histology have a marked decrease in risk for progression and/or death in a pre-specified exploratory analysis (HR 0.57; 95% CI 0.348, 0.944; one-sided $p=0.014$)
- Patients in the pre-specified exploratory **p53 wild-type** subgroup (based on the mode of action of selinexor) achieved a **62% decrease of risk for progression and/or death to placebo** (HR: 0.38; 95% CI 0.210-0.670; one-sided $p=0.0003$)
- **QOL** data were similar in both groups
- **OS** data are immature (final OS analysis expected Q1 2023)
- AEs were generally manageable with supportive care and dose modifications. No new safety signals were identified

ELIGIBILITY

Key Inclusion Criteria


- Female patients ≥ 18 years
- Histology: Endometrioid, serous, carcinosarcoma, or undifferentiated
- CR or PR after platinum-taxane combination therapy:
 - Primary Stage IV disease OR
 - At first relapse
- ECOG 0-1

Key Exclusion Criteria

- Sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear cell carcinomas
- Previous treatment with an XPO1 inhibitor or with anti-PD-1 or anti-PD-L1 immunotherapy
- Active brain metastases

SELINEXOR INDUCES NUCLEAR ACCUMULATION OF P53

- p53 wild type tumors account for 45-65% of all endometrial cancers
 - Generally endometrioid in histology and occurs in younger patients
- Inhibition of XPO1 leads to nuclear accumulation of tumor suppressor proteins such as p53
- Selinexor induces nuclear localization of p53 in patients treated with selinexor



Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018; 173: 321-37
 Pan-cancer analysis of whole genomes. Nature. 2020; 578: 82-93
 Soumerai et al. Clin Cancer Res. 2018; 24: 5939-47

ESMO VIRTUAL PLenary

Ignace Vergote, MD, PhD

Content of this presentation is copyright and responsibility of the author.
 Permission is required for re-use.


SUBGROUP PATIENT CHARACTERISTICS: BY HISTOLOGICAL SUBTYPE

| CHARACTERISTIC | Endometrioid Carcinoma | | Serous Carcinoma | | Others | |
|--|------------------------|-------------------|---------------------|-------------------|---------------------|-------------------|
| | Selinexor N = 96 | Placebo N = 48 | Selinexor N = 49 | Placebo N = 28 | Selinexor N = 29 | Placebo N = 13 |
| Age, years median (range), n (%) | 64.0 (40-81) | 60.5 (40-74) | 66.0 (41-79) | 68.5 (58-80) | 67.0 (46-81) | 66.0 (33-81) |
| <70 years, n (%) | 66 (68.8) | 38 (79.2) | 32 (65.3) | 15 (53.6) | 18 (62.1) | 8 (61.6) |
| ≥70 years, n (%) | 30 (31.3) | 10 (20.8) | 17 (34.7) | 13 (46.4) | 11 (37.9) | 5 (38.5) |
| ECOG performance status, n (%) | | | | | | |
| 0 | 57 (59.4) | 27 (56.3) | 27 (55.1) | 18 (64.3) | 15 (51.7) | 9 (69.2) |
| 1 | 37 (38.5) | 21 (43.8) | 21 (42.9) | 10 (35.7) | 13 (44.8) | 4 (30.8) |
| Histology, n (%) | | | | | | |
| Endometrioid | 96 (100.0) | 48 (100.0) | 0 | 0 | 0 | 0 |
| Serous | 0 | 0 | 49 (100.0) | 28 (100.0) | 0 | 0 |
| Undifferentiated | 0 | 0 | 0 | 0 | 4 (13.8) | 1 (7.7) |
| Carcinosarcoma | 0 | 0 | 0 | 0 | 10 (34.5) | 6 (46.2) |
| Endometrial Adenocarcinoma* | 0 | 0 | 0 | 0 | 15 (51.7) | 6 (46.2) |
| Number of Prior Antineoplastic Regimens, n (%) | | | | | | |
| 1 | 96 (100.0) | 46 (95.8) | 48 (98.0) | 27 (96.4) | 28 (96.6) | 12 (92.3) |
| 2 | 0 | 1 (2.1) | 1 (2.0) | 1 (3.6) | 1 (3.4) | 1 (7.7) |
| Disease at Time of Taxane-Platinum Combination Therapy -eCRF, n (%) | | | | | | |
| Primary Stage IV Disease | 41 (42.7) | 19 (39.6) | 23 (46.9) | 17 (60.7) | 14 (48.3) | 7 (53.8) |
| Recurrent Disease | 55 (57.3) | 29 (60.4) | 26 (53.1) | 11 (39.3) | 15 (51.7) | 6 (46.2) |
| Disease Status After the Most Recent Chemotherapy -eCRF, n (%) | | | | | | |
| CR | 40 (41.7) | 23 (47.9) | 20 (40.8) | 13 (46.4) | 10 (34.5) | 4 (30.8) |
| PR | 56 (58.3) | 25 (52.1) | 29 (59.2) | 15 (53.6) | 19 (65.5) | 9 (69.2) |

*Not otherwise specified

CR, complete response; ECOG, Eastern Cooperative Oncology Group; eCRF, electronic case report form; PR, partial response

SUBGROUP PFS: BY HISTOLOGICAL SUBTYPE - OTHER*



Median PFS

Selinexor: 3.7 mo (95% CI 1.94, not reached)

Placebo: 5.2 mo (95% CI 3.71, not reached)

HR 1.103 (95% CI 0.459, 2.652)


One-sided P value = 0.592

*Undifferentiated Carcinoma, Carcinosarcoma, Endometrial Adenocarcinoma (Not otherwise specified)


ENGOT-EN5/GOG-3055/SIENDO

SUBGROUP PFS: BY DISEASE AT TIME OF TAXANE-PLATINUM COMBINATION THERAPY

Primary Stage IV Disease




Recurrent Disease




ENGOT-EN5/GOG-3055/SIENDO

SUBGROUP PFS: BY PR VS CR STRATIFICATION

PR




CR



ENGOT-EN5/GOG-3055/SIENDO

SUBGROUP PFS: PATIENTS WITH ENDOMETRIAL CANCER WITH MSS/PMMR



Median PFS

Selinexor: 6.9 mo (95% CI 5.42-10.94)

Placebo: 5.4 mo (95% CI 3.61-7.49)

HR=0.593 (95% CI 0.388-0.905)

One-sided P value = 0.007

ENGOT-EN5/GOG-3055/SIENDO

USE OF IRT VS ECRF

- SIENDO primary analysis used IRT, but a misclassification of data made resulting analysis erroneous
- Errors corrected by Investigators before database lock and unblinding
- eCRF is correct and appropriate to use in primary endpoint analysis of PFS
- Data discrepancy due to mistake in classifying stratification factor of CR/PR by clinical sites for 7 patients in IRT

| Number of Patients | Arm | Incorrect Assignment in IRT | Correct Data eCRF |
|--------------------|-----------|-----------------------------|-------------------|
| 3 | Selinexor | CR | PR |
| 3 | Placebo | PR | CR |
| 1 | Selinexor | PR | CR |

- Disease burden at baseline is prognostic
 - These errors had substantial effect on endpoint of study
- All other demographic parameters remained balanced when using eCRF ITT

INCORRECT STRATIFICATION AT RANDOMIZATION

- Per SAP (v3.0), the stratified analysis (based on IRT value of the disease status after chemotherapy, CR vs. PR) is the primary analysis for PFS, which was determined to be erroneous for the SIENDO study
 - The baseline disease status has a marked effect on primary endpoint PFS (expected median PFS <4 months for PR patients (pts) and >7 months for CR pts from literature, in SIENDO Placebo arm, mPFS 3.6 months for PR pts and 9.3 months for CR pts)
 - Seven (7) patients had this stratification factor incorrectly recorded in the IRT system, and the error is imbalanced between the 2 treatment arms (6 out of 7 against selinexor arm)
 - The stratified (IRT) analysis did not minimize bias, instead, it introduced bias due to the imbalance in errors and this imbalance in stratification factor error was unknown to the Sponsor until the study was unblinded for primary objective analysis
- The stratified (eCRF) analysis uses correct disease status derived based on corrected information study sites entered to pts' eCRF prior to database lock

REASONS FOR REDUCTION, INTERRUPTIONS, DISCONTINUATIONS

| Treatment-Emergent Event Leading to | Dose Reduction | | Dose Interruption | | Discontinuation | |
|-------------------------------------|----------------|---------|-------------------|---------|-----------------|---------|
| | Selinexor | Placebo | Selinexor | Placebo | Selinexor | Placebo |
| Thrombocytopenia | 28 (16.4) | 0 | 24 (14.0) | 0 | 1 (0.6) | 0 |
| Nausea | 23 (13.5) | 1 (1.1) | 19 (11.1) | 1 (1.1) | 7 (4.1) | 0 |
| Fatigue | 19 (11.1) | 1 (1.1) | 17 (9.9) | 1 (1.1) | 5 (2.9) | 0 |
| Asthenia | 15 (8.8) | 1 (1.1) | 14 (8.2) | 2 (2.3) | 2 (1.2) | 1 (1.1) |
| Vomiting | 11 (6.4) | 0 | 13 (7.6) | 0 | 3 (1.8) | 0 |
| Neutropenia | 6 (3.5) | 0 | 13 (7.6) | 0 | -- | -- |

COVID-19 Cases: Selinexor: 6 (3.5%); Placebo: 3 (3.4%)